Chromosomal Allele Loss in Primary Cutaneous Melanoma is Heterogeneous and Correlates with Proliferation  by Böni, Roland et al.
Chromosomal Allele Loss in Primary Cutaneous Melanoma is
Heterogeneous and Correlates with Proliferation
Roland Bo¨ni, David Matt, Alexander Voetmeyer,* Gu¨nter Burg, and Zhengping Zhuang*
Department of Dermatology, University Hospital, Zu¨rich, Switzerland; *Department of Pathology, National Cancer Institute, National Institutes of Health,
Bethesda, Maryland, U.S.A.
Loss of heterozygosity at specific loci in neoplastic cells
suggests the presence of a tumor suppressor gene within
the deleted region. Using the microdissection technique,
loss of heterozygosity has been identified in paraffin-
embedded primary melanomas on chromosomes 1p and
9q. Our purpose was to determine loss of heterozygosity
in primary cutaneous melanomas and to relate chromo-
somal alterations with cell morphology and proliferation
of the tumor. Two to seven morphologic different areas
in 12 primary cutaneous high risk melanomas (Breslow
> 1.5 mm), as well as adjacent normal tissue, were
microdissected and subjected to single step DNA extrac-
tion. Extracted genomic DNA was amplified by poly-
merase chain reaction using two polymorphic markers on
chromosomes 1p (D1S450, between D1S548 and D1S228)
and 9q (D9S12). Proliferation was evaluated by MIB-1
(Ki67) immunoreactivity and cell morphology, pigmenta-
tion and inflammation surrounding microdissected areas
were investigated by microscopic inspection of hematox-
ylin and eosin stained sections. Twelve of 34 different
areas (35%) showed loss of heterozygosity with at least
Human cutaneous melanoma is known for its morphol-ogic heterogeneity (Bridge et al, 1991). The neoplasticprogression of this disease advances from transforma-tion of melanocytes to aggregated atypical cells withradial growth phase, vertical growth phase, invasion
into lymphatic and blood vessels, and finally the formation of distant
metastases. The development of malignant melanoma is accompanied
by an accumulation of genetic damage that is evident within tumor
cells at both the cytogenetic and the molecular levels, and mutations
at several gene loci are thought to contribute to malignant progression.
Based on cell culture studies, genetic abnormalities have been demon-
strated to increase in severity with clinical progression of melanocytic
transformation. Chromosomal alterations on virtually every chromo-
some can be found in metastasis derived cell lines (Balaban et al, 1986;
Limon et al, 1988; Pedersen and Wang, 1989; Kacker et al, 1990;
Ozisik et al, 1994).
Due to a lack of isolation technique, however, it has not been
previously possible to conduct a detailed genetic analysis on histologi-
cally well-characterized tumor cells from paraffin-embedded archival
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one marker. Two of 32 areas showed loss of heterozygosity
with D1S450 (two areas noninformative), seven of 30
with D9S12 (four areas noninformative), and three areas
showed loss of heterozygosity at both loci. In three of
these cases, analysis of different tumor foci revealed areas
with/without loss of heterozygosity. In these cases, the
percentage of MIB-I-positive cells was at least four times
higher in areas with loss of heterozygosity compared with
areas without loss of heterozygosity. Most areas with loss
of heterozygosity consisted of small cuboidal to epitheloid
cells. Spindle shaped and large anaplastic cells showed loss
of heterozygosity less frequently. Neither melanization of
tumor cells nor the presence of inflammation had an
influence on the frequency of loss of heterozygosity.
Primary cutaneous melanomas show intratumoral mor-
phologic and chromosomal heterogeneity. Loss of hetero-
zygosity on chromosomes 1p and 9q correlated with cell
proliferation, suggesting that selected cell clones are
responsible for tumor progression. Key words: chromosome
9q/chromosome 1p/loss of heterozygosity/melanoma. J Invest
Dermatol 110:215–217, 1998
material. Using the microdissection technique, cells can now be
procured with a sterile needle from highly specific areas of the tissue
section under direct high-power visualization (Zhuang et al, 1995).
This study was conducted in an attempt to investigate the intra-
tumoral heterogeneity of allelic loss on selected chromosomes and
to relate chromosomal alterations with morphologic findings and
proliferation of the tumor. Because loss of heterozygosity at 1p
(D1S450) and 9q (D9S12) are frequently found in melanoma cells
(Bale et al, 1989; Goldstein et al, 1994; Healy et al, 1996), the study
focused on these two loci.
MATERIALS AND METHODS
Histologic specimen Paraffin-embedded histologic specimens of 12 primary
cutaneous nodular melanomas with a high risk for metastasis, i.e., Breslow
. 1.5 mm (mean Breslow 3.13, range 1.6–8.0), from 12 different patients (five
male, seven female), were investigated. The histologic specimens were obtained
from the archives of the Department of Dermatology, University Hospital of
Zurich, Switzerland. From each specimen, one section was used for hematoxylin
and eosin staining and microdissection. Staining with the proliferation marker
MIB-I (Ki-67) was performed on an adjacent slide.
To assure correct diagnosis, all histologic slides were reviewed.
Microdissection In each case, a 4 µm tissue section was obtained for
hematoxylin and eosin staining and microdissection. A total of 34 morpho-
logically different areas were sampled in these 12 primary melanoma (2–7 areas
per lesion) and the microdissected transformed melanocytes were characterized
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Figure 1. Hematoxylin and eosin stained section (magnification 3200)
showing two morphologic different microdissected areas (small
cuboidal above and epitheloid cells below) and the sequence gel analysis
results obtained after subjection of microdissected cells to single step
DNA extraction and amplification using primers for D1S450 and D9S12.
The small cuboidal cell (above) shows loss of heterozygosity on chromosomes
1 (D1S450) and 9 (D9S12), whereas the epitheloid cells below display no loss
of heterozygosity using these markers. N, normal; T, tumor.
as follows: small cuboidal, epitheloid, spindle shaped, and large anaplastic.
Melanization (yes/no) of the cell clones as well as the inflammation (yes/no)
surrounding the dissected areas was documented.
Microdissection was performed under light microscope visualization (magni-
fication 3200) using a 30-gauge needle (Fig 1). Samples from normal cell
structures apart from melanoma, e.g., sebaceous glands, inflammatory cells were
also obtained in all cases from the same slide for comparison with the
tumor samples.
DNA extraction Procured cells (transformed melanocytes as well as samples
obtained from normal cell structures apart from melanoma) were immediately
suspended in 10 µl of buffer containing 0.05 M tris-HCl, 1 mM ethylenediamine
tetraacetic acid, 1% Tween 20, and 0.1 g proteinase K per liter, pH 8.0, and
incubated overnight at 37°C. The mixture was boiled for 10 min to inactivate
proteinase K and 1.5 µl of this solution was used for polymerase chain
reaction (PCR).
Primers and PCR conditions One commercially available (Research Genet-
ics, Huntsville, AL) polymorphic DNA marker at chromosome 1p (D1S450)
and one marker at chromosome 9q (D9S12) were used in this study. PCR was
performed in 10 µl volumens and contained 1 µl 10 3 PCR buffer [100 mM
Tris-HCl, pH 8.3; 500 mM KCl; 15 mM MgCl2; 0.1% wt/vol gelatin; 1.5 µl
of DNA extraction buffer; 50 pM of each primer; 20 nM each of dCTP, dGTP,
dTTP, and dATP; 0.2 µl [32P] dCTP (6000 Ci per mmol); and 0.1 unit Taq
DNA polymerase]. Reactions were cycled in a thermal cycler (Gene Amp
PCR System 9600, Perkin Elmer, Zurich, Switzerland) as follows:
D1S450: 94°C for 60 s, followed by 55°C for 60 s, 72°C for 60 s, total 35 cycles.
D9S12: 94°C for 60 s, followed by 61°C for 45 s, 72°C for 45 s, total 35 cycles.
Labeled amplified DNA was mixed with an equal volume of formamide
loading dye (95% formamide, 20 mM ethylenediamine tetraacetic acid, 0.05%
bromophenol blue, and 0.05% xylene cyanol). The samples were denatured for
5 min at 94°C and loaded onto a gel consisting of 6% acrylamide (49:1
acrylamide: bis). Samples were electrophoresed at 1800 V for 1–2 h. Gels were
transferred to 3 mm Whatman paper (Merck, Zurich, Switzerland), dried, and
subjected to autoradiography with Typon X-Ray DX 41 film (Typon, Burgdorf,
Switzerland). Loss of heterozygosity was defined as an absence of one allele in
the tumor DNA evaluated by autoradiography.
Immunohistochemistry An adjacent 4 µm tissue section was used for
immunohistochemistry with MIB-1 (Dianova, Hamburg, Germany) visualized
by the alkaline phosphatase anti-alkaline phosphatase method (Cordell et al,
1984). The deparaffined sections were processed in a 100-W household
microwave oven at maximum power for 3 3 5 min in 10 mM citric acid to
enhance antigen detection. Undiluted MIB-1 antibody was then applied
for 60 min.
Assessment of MIB-1 immunoreactivity Histologic areas corresponding
to microdissected zones where visually evaluated in the adjacent slide and a
field of . 100 nuclei was counted at 3400 magnification. The number of
MIB-1-immunoreactive nuclei in each field was expressed as a percentage of
Table I. Results of the loss of heterozygosity studies using the
markers D1S450 and D9S12 for each individual area within 12
nodular melanomas in comparison with the proliferation rate
(% total tumor nuclei in one field of at least 100 tumor cells
in the center of the microdissected area at 3400
magnification)
Specimena D1S450b D9S12 MIB-1
1 a NL NL 0.4
b NL NL 1
c NL NL 0.6
d NL NL 1.8
2 a NL NL 0.8
b NL NL 0.2
c NL NL 0.4
3 a NI LOH 13.4
b NI LOH 12.4
4 a NL NI 4
b NL NI 3.6
5 a LOH NL 14.6
b NL LOH 15
6 a NL NL 0.4
b NL NL 0.5
c NL NL 2.3
7 a NL NI 1.6
b NL NI 1.4
c NL NI 1
8 a LOH LOH 28
b NL LOH 16
9 a NL NL 1.8
b NL NL 2.4
10 a LOH NI 21.8
b NL NI 4
11 a NL NL 5.4
b NL LOH 23.8
12 a NL NL 5.6
b NL NL 3.2
c NL LOH 16.4
d LOH LOH 23.8
e NL NL 0.8
f LOH LOH 13.4
g NL LOH 9.6
aTwo to seven areas were sampled in each specimen (marked a, b, c . . .).
bLOH, loss of heterozygosity; NL, no loss of heterozygosity; NI, noninformative.
the total tumor nuclei counted, and a mean percentage of MIB-1-immuno-
reactive tumor nuclei was calculated for each area. MIB-1 proliferative activity
was assessed without knowledge of the loss of heterozygosity scores of the
respective tumor zones.
RESULTS
Of 34 areas in 12 primary cutaneous melanomas, 12 (35%) showed
loss of heterozygosity with at least one marker. Two areas for D1S450
and four areas for D9S12 had equal length polymorphism (homozygous)
and were exluded from the calculation. Two of 32 areas showed loss
of heterozygosity with D1S450, seven of 30 areas with D9S12, and
three areas with both primers (Table I).
In three cases (cases 10–12), analysis of different tumor foci revealed
areas with/without loss of heterozygosity. In these cases, the percentage
of MIB-1-positive cells was at least four times higher in areas with loss
of heterozygosity compared with areas without loss of heterozygosity
(Table I). Most areas with loss of heterozygosity consisted of small
cuboidal (D9S12, four of five; D1S450, two of five) to epitheloid
(D9S12, two of three; D1S450, two of four) cells. Spindle shaped and
large anaplastic cells showed loss of heterozygosity less frequently
(D9S12, three of 12; D1S450, one of 13; D9S12, three of 10; D1S450,
none of 10, respectively). Neither the amount of melanization of
the microdissected transformed cells nor the presence of lymphoid
infiltration surrounding selected cell groups influenced the frequency
of loss of heterozygosity.
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DISCUSSION
Cancers develop as a stepwise accumulation of genetic changes (Fearon
and Vogelstein, 1990). The majority of candidate suppressor genes on
chromosomal loci showing loss of heterozygosity in melanoma are not
yet characterized. Most studies of genetic progression in malignant
melanoma have relied on cell cultures derived from metastatic tumor
tissue, where genetic alterations may have occurred secondary to the
tissue culture process, and the relation between relevant accumulation
of genetic abnormalities and morphologic changes can thus not be
studied. Using the microdissection technique, morphologic changes
can be directly correlated to genetic alterations.
Studies using this technique (Goldstein et al, 1994; Healy et al,
1996), including unpublished data from our own group, demonstrated
frequent loss of heterozygosity on chromosomal loci on 1p and 9q.
For our survey, we used the highly polymorphic markers at D1S450
and D9S12.
Using these polymorphic DNA markers, an intra-tumoral hetero-
geneity of loss of heterozygosity in morphologically different areas
could be demonstrated (Fig 1). The study confirms diversity in terms
of morphology as well as of allele loss in different areas of aggregated
tumor cells, suggesting the coexistence of various genetic alterations
within the primary.
Whereas the areas with the highest frequencies of loss of heterozygos-
ity consisted of small cuboidal to epitheloid cells, less genetic alterations
were found in large anaplastic and in spindle shaped cells. No relation
of loss of heterozygosity to the presence or absence of pigmentation
of selected cell nests or the presence or absence of inflammation
surrounding microdissected areas was found. Areas with loss of hetero-
zygosity showed a higher number of MIB-I-positive cells compared
with microdissected areas without allele loss. It has been shown that
MIB-1 proliferative activity correlates with the clinical outcome in
patients with primary thick cutaneous melanoma (Ramsay et al, 1995;
Bo¨ni et al, 1996). This seems to contrast with the literature, where cell
morphology was not a prognostic factor in cutaneous melanoma
(Gordon et al, 1991). It might partly be explained by the fact that
these authors characterized the entire primary as a homogeneous tumor,
whereas in our study, morphologically different cell aggregates of
transformed melanocytes within the same primary were selected. It is
likely that only selected cell clones within the tumor are able to
metastasize.
We found a close relation between the frequency of allelic loss on
chromosomal material from areas in 1p and 9q and a high number of
MIB-1-positive cells. Further studies have to be performed to correlate
these findings with the biologic behavior, including prognosis and
potential metastasis of malignant melanoma.
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